Role of epithelial to mesenchymal transition in hepatocellular carcinoma

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 798-808

  Giannelli, Gianluigi ^a   Koudelkova, Petra ^b   Dituri, Francesco ^a   Mikulits, Wolfgang ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell invasion; EMT; Epithelial plasticity; HCC; MET; Patient survival; Therapy; Tumor heterogeneity

Indexed keywords

GALUNISERTIB; KALININ; MICRORNA; SCATTER FACTOR RECEPTOR; TIVANTINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E12; TRANSCRIPTION FACTOR E47; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR TWIST2; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; CADHERIN;

CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL HETEROGENEITY; CELL PLASTICITY; CHEMOEMBOLIZATION; CLINICAL OUTCOME; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STELLATE CELL; STROMA; THERAPY EFFECT; TUMOR MICROENVIRONMENT; LIVER TUMOR; TUMOR CELL LINE;

CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84991736278     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.007     Document Type: Review

References (115)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. [2] Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
3. [3] Marquardt, J.U., Andersen, J.B., Thorgeirsson, S.S., Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer 15 (2015), 653–667.
4. [4] Roessler, S., Budhu, A., Wang, X.W., Deciphering cancer heterogeneity: the biological space. Front Cell Dev Biol, 2, 2014, 12.
5. [5] Gao, Q., Wang, X.Y., Zhou, J., Fan, J., Multiple carcinogenesis contributes to the heterogeneity of HCC. Nat Rev Gastroenterol Hepatol, 12, 2015, 13.
6. [6] Budhu, A., Forgues, M., Ye, Q.H., Jia, H.L., He, P., Zanetti, K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 (2006), 99–111.
7. [7] Roessler, S., Jia, H.L., Budhu, A., Forgues, M., Ye, Q.H., Lee, J.S., et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70 (2010), 10202–10212.
8. [8]C.H. Osterreicher,M. Penz-Osterreicher, Grivennikov, S.I., Guma, M., Koltsova, E.K., Datz, C., et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A 108 (2011), 308–313.
9. [9] Xie, G., Diehl, A.M., Evidence for and against epithelial-to-mesenchymal transition in the liver. Am J Physiol Gastrointest Liver Physiol 305 (2013), G881–G890.
10. [10] Brabletz, T., To differentiate or not–routes towards metastasis. Nat Rev Cancer 12 (2012), 425–436.
11. [11] Nieto, M.A., Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 342, 2013, 1234850.
12. [12]X. Zheng, J.L. Carstens, Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
13. [13] Choi, S.S., Diehl, A.M., Epithelial-to-mesenchymal transitions in the liver. Hepatology 50 (2009), 2007–2013.
14. [14] G.A. Michelotti, G. Xie, Swiderska, M., Choi, S.S., Karaca, G., Kruger, L., et al. Smoothened is a master regulator of adult liver repair. J Clin Invest 123 (2013), 2380–2394.
15. [15] Swiderska-Syn, M., Syn, W.K., Xie, G., Kruger, L., Machado, M.V., Karaca, G., et al. Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy. Gut 63 (2014), 1333–1344.
16. [16] Coward, W.R., Saini, G., Jenkins, G., The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 4 (2010), 367–388.
17. [17] Kriz, W., Kaissling, B., Le Hir, M., Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J Clin Invest 121 (2011), 468–474.
18. [18] Caja, L., Bertran, E., Campbell, J., Fausto, N., Fabregat, I., The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 226 (2011), 1214–1223.
19. [19] Dooley, S., Hamzavi, J., Ciuclan, L., Godoy, P., Ilkavets, I., Ehnert, S., et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 135 (2008), 642–659.
20. [20] Omenetti, A., Porrello, A., Jung, Y., Yang, L., Popov, Y., Choi, S.S., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118 (2008), 3331–3342.
21. [21] M. Zeisberg, C. Yang, Martino, M., Duncan, M.B., Rieder, F., Tanjore, H., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007), 23337–23347.
22. [22]K. Taura, K. Miura, Iwaisako, K., Osterreicher, C.H., Kodama, Y., Penz-Osterreicher, M., et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51 (2010), 1027–1036.
23. [23] Scholten, D., Osterreicher, C.H., Scholten, A., Iwaisako, K., Gu, G., Brenner, D.A., et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139 (2010), 987–998.
24. [24] Chu, A.S., Diaz, R., Hui, J.J., Yanger, K., Zong, Y., Alpini, G., et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53 (2011), 1685–1695.
25. [25] Brenner, D.A., Kisseleva, T., Scholten, D., Paik, Y.H., Iwaisako, K., Inokuchi, S., et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair, 5, 2012, S17.
26. [26] Iwaisako, K., Brenner, D.A., Kisseleva, T., What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 27 (2012), 65–68.
27. [27] K. Iwaisako, C. Jiang, M. Zhang, Cong, M., Moore-Morris, T.J., Park, T.J., et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A 111 (2014), E3297–E3305.
28. [28] Pinzani, M., Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death?. J Hepatol 55 (2011), 459–465.
29. [29] Pani, G., Galeotti, T., Chiarugi, P., Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29 (2010), 351–378.
30. [30] Jou, J., Diehl, A.M., Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest 120 (2010), 1031–1034.
31. [31] A.N. Fischer, E. Fuchs, M. Mikula, Huber, H., Beug, H., Mikulits, W., PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26 (2007), 3395–3405.
32. [32] Gotzmann, J., Huber, H., Thallinger, C., Wolschek, M., Jansen, B., Schulte-Hermann, R., et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 115 (2002), 1189–1202.
33. [33] Petz, M., Them, N.C., Huber, H., Mikulits, W., PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res 40 (2012), 9738–9749.
34. [34] van Zijl, F., Mair, M., Csiszar, A., Schneller, D., Zulehner, G., Huber, H., et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 28 (2009), 4022–4033.
35. [35] Giannelli, G., Bergamini, C., Fransvea, E., Sgarra, C., Antonaci, S., Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129 (2005), 1375–1383.
36. [36] Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
37. [37] van Zijl, F., Krupitza, G., Mikulits, W., Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 728 (2011), 23–34.
38. [38] Giannelli, G., Villa, E., Lahn, M., Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res 74 (2014), 1890–1894.
39. [39] P. Reichl, C. Haider, Grubinger, M., Mikulits, W., TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des 18 (2012), 4135–4147.
40. [40] Calvisi, D.F., When good transforming growth factor-beta turns bad in hepatocellular carcinoma: Axl takes the stage. Hepatology 61 (2015), 759–761.
41. [41] Hoshida, Y., Nijman, S.M., Kobayashi, M., Chan, J.A., Brunet, J.P., Chiang, D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69 (2009), 7385–7392.
42. [42] Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47 (2008), 2059–2067.
43. [43] Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15 (2014), 178–196.
44. [44] van Roy, F., Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer 14 (2014), 121–134.
45. [45] Zhu, M., Yin, F., Fan, X., Jing, W., Chen, R., Liu, L., et al. Decreased TIP30 promotes Snail-mediated epithelial-mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma. Oncogene 34 (2015), 1420–1431.
46. [46] Reichl, P., Dengler, M., van Zijl, F., Huber, H., Fuhrlinger, G., Reichel, C., et al. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology 61 (2015), 930–941.
47. [47] Z.J. Zhou, Z. Dai, S.L. Zhou, Hu, Z.Q., Chen, Q., Zhao, Y.M., et al. HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res 74 (2014), 2750–2762.
48. [48] Yang, M., Li, S.N., Anjum, K.M., Gui, L.X., Zhu, S.S., Liu, J., et al. A double-negative feedback loop between Wnt-beta-catenin signaling and HNF4alpha regulates epithelial-mesenchymal transition in hepatocellular carcinoma. J Cell Sci 126 (2013), 5692–5703.
49. [49] J. Fu, Y. Chen, J. Cao, Luo, T., Qian, Y.W., Yang, W., et al. P28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 53 (2011), 181–192.
50. [50] S. Tanaka, H. Shiraha, Nakanishi, Y., Nishina, S., Matsubara, M., Horiguchi, S., et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer 131 (2012), 2537–2546.
51. [51] Wang, Y.P., Yu, G.R., Lee, M.J., Lee, S.Y., Chu, I.S., Leem, S.H., et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology 58 (2013), 1349–1361.
52. [52] Wang, R., Li, Y., Hou, Y., Yang, Q., Chen, S., Wang, X., et al. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget 6 (2015), 7000–7010.
53. [53] L. Xia, W. Huang, Tian, D., Zhang, L., Qi, X., Chen, Z., et al. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology 59 (2014), 958–973.
54. [54] Yuan, J.H., Yang, F., Wang, F., Ma, J.Z., Guo, Y.J., Tao, Q.F., et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25 (2014), 666–681.
55. [55] Li, T., Xie, J., Shen, C., Cheng, D., Shi, Y., Wu, Z., et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35 (2015), 1575–1584.
56. [56] Kim, T., Veronese, A., Pichiorri, F., Lee, T.J., Jeon, Y.J., Volinia, S., et al. P53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208 (2011), 875–883.
57. [57] Xia, H., Ooi, L.L., Hui, K.M., MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58 (2013), 629–641.
58. [58] Z.H. Tao, J.L. Wan, Zeng, L.Y., Xie, L., Sun, H.C., Qin, L.X., et al. MiR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med 210 (2013), 789–803.
59. [59] Zhang, J.P., Zeng, C., Xu, L., Gong, J., Fang, J.H., Zhuang, S.M., MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 33 (2013), 4069–4076.
60. [60] J.Y. Huang, K. Zhang, D.Q. Chen, Chen, J., Feng, B., Song, H., et al. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget 6 (2015), 18613–18630.
61. [61] J.N. Zhou, Q. Zeng, Wang, H.Y., Zhang, B., Li, S.T., Nan, X., et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology 62 (2015), 801–815.
62. [62] R.Y. Wang, L. Chen, H.Y. Chen, Hu, L., Li, L., Sun, H.Y., et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology 145 (2013), 1436–1448 e1431–e1412.
63. [63] Chen, J., Chan, A.W., To, K.F., Chen, W., Zhang, Z., Ren, J., et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology 57 (2013), 2287–2298.
64. [64] J. Li, B. Yang, Q. Zhou, Y. Wu, D. Shang, Guo, Y., et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis 34 (2013), 1343–1351.
65. [65] Xia, H., Chen, J., Shi, M., Gao, H., Sekar, K., Seshachalam, V.P., et al. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. J Hepatol 63 (2015), 863–873.
66. [66] Tiwari, I., Yoon, M.H., Park, B.J., Jang, K.L., Hepatitis C virus core protein induces epithelial-mesenchymal transition in human hepatocytes by upregulating E12/E47 levels. Cancer Lett 362 (2015), 131–138.
67. [67] D.F. Calvisi, S. Ladu, Conner, E.A., Factor, V.M., Thorgeirsson, S.S., Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest 84 (2004), 1137–1147.
68. [68] Huang, G.T., Lee, H.S., Chen, C.H., Sheu, J.C., Chiou, L.L., Chen, D.S., Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma. Hepatogastroenterology 46 (1999), 1923–1927.
69. [69] Matsumura, T., Makino, R., Mitamura, K., Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 7 (2001), 594–599.
70. [70] Miyoshi, A., Kitajima, Y., Sumi, K., Sato, K., Hagiwara, A., Koga, Y., et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 90 (2004), 1265–1273.
71. [71] Miyoshi, A., Kitajima, Y., Kido, S., Shimonishi, T., Matsuyama, S., Kitahara, K., et al. Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer 92 (2005), 252–258.
72. [72] Wei, Y., Van Nhieu, J.T., Prigent, S., Srivatanakul, P., Tiollais, P., Buendia, M.A., Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 36 (2002), 692–701.
73. [73] W. Prange, K. Breuhahn, Fischer, F., Zilkens, C., Pietsch, T., Petmecky, K., et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 201 (2003), 250–259.
74. [74] K. Zhu, Z. Dai, Q. Pan, Wang, Z., Yang, G.H., Yu, L., et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 17 (2011), 7294–7302.
75. [75] M.H. Yang, C.L. Chen, Chau, G.Y., Chiou, S.H., Su, C.W., Chou, T.Y., et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 50 (2009), 1464–1474.
76. [76] Yamada, S., Okumura, N., Wei, L., Fuchs, B.C., Fujii, T., Sugimoto, H., et al. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. Ann Surg Oncol 21 (2014), 3882–3890.
77. [77] Zhai, X., Zhu, H., Wang, W., Zhang, S., Zhang, Y., Mao, G., Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol, 31, 2014, 970.
78. [78] Kim, J., Hong, S.J., Park, J.Y., Park, J.H., Yu, Y.S., Park, S.Y., et al. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Sci 101 (2010), 1521–1528.
79. [79] Mima, K., Hayashi, H., Kuroki, H., Nakagawa, S., Okabe, H., Chikamoto, A., et al. Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-beta signaling. Oncol Lett 5 (2013), 149–154.
80. [80] Li, Y.M., Xu, S.C., Li, J., Han, K.Q., Pi, H.F., Zheng, L., et al. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis, 4, 2013, e831.
81. [81] Pedrozo, H.A., Schwartz, Z., Robinson, M., Gomes, R., Dean, D.D., Bonewald, L.F., et al. Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-beta1 from the extracellular matrix of growth plate chondrocytes. Endocrinology 140 (1999), 5806–5816.
82. [82] Yu, Q., Stamenkovic, I., Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000), 163–176.
83. [83] G. Giannelli, E. Fransvea, Marinosci, F., Bergamini, C., Colucci, S., Schiraldi, O., et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161 (2002), 183–193.
84. [84] Ke, A.W., Shi, G.M., Zhou, J., Huang, X.Y., Shi, Y.H., Ding, Z.B., et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology, 140, 2011, e1615.
85. [85] Guess, C.M., Quaranta, V., Defining the role of laminin-332 in carcinoma. Matrix Biol 28 (2009), 445–455.
86. [86] Santamato, A., Fransvea, E., Dituri, F., Caligiuri, A., Quaranta, M., Niimi, T., et al. Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) 121 (2011), 159–168.
87. [87] Bergamini, C., Sgarra, C., Trerotoli, P., Lupo, L., Azzariti, A., Antonaci, S., et al. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 46 (2007), 1801–1809.
88. [88] Katsuno, Y., Lamouille, S., Derynck, R., TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25 (2013), 76–84.
89. [89] Caja, L., Kahata, K., Moustakas, A., Context-dependent action of transforming growth factor beta family members on normal and cancer stem cells. Curr Pharm Des 18 (2012), 4072–4086.
90. [90] Frank, N.Y., Schatton, T., Frank, M.H., The therapeutic promise of the cancer stem cell concept. J Clin Invest 120 (2010), 41–50.
91. [91] Fernando, J., Malfettone, A., Cepeda, E.B., Vilarrasa-Blasi, R., Bertran, E., Raimondi, G., et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 136 (2015), E161–E172.
92. [92] Kim, H., Choi, G.H., Na, D.C., Ahn, E.Y., Kim, G.I., Lee, J.E., et al. Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54 (2011), 1707–1717.
93. [93] K. Tsuchiya, M. Komuta, Yasui, Y., Tamaki, N., Hosokawa, T., Ueda, K., et al. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 80 (2011), 278–288.
94. [94] Govaere, O., Komuta, M., Berkers, J., Spee, B., Janssen, C., de Luca, F., et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 63 (2014), 674–685.
95. [95] Giannelli, G., Fransvea, E., Bergamini, C., Marinosci, F., Antonaci, S., Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 9 (2003), 3684–3691.
96. [96] Govaere, O., Wouters, J., Petz, M., Vandewynckel, Y.P., Van den Eynde, K., Van den Broeck, A., et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J Hepatol 64 (2016), 609–617.
97. [97] Sulpice, L., Rayar, M., Desille, M., Turlin, B., Fautrel, A., Boucher, E., et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 58 (2013), 1992–2000.
98. [98] Liu, L., Ren, Z.G., Shen, Y., Zhu, X.D., Zhang, W., Xiong, W., et al. Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition. Cancer Sci 101 (2010), 120–128.
99. [99] Giannelli, G., Sgarra, C., Porcelli, L., Azzariti, A., Antonaci, S., Paradiso, A., EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 262 (2008), 257–264.
100. [100] Ogunwobi, O.O., Liu, C., Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 28 (2011), 721–731.
101. [101] Ding, W., You, H., Dang, H., LeBlanc, F., Galicia, V., Lu, S.C., et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52 (2010), 945–953.
102. [102] Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., Okamoto, E., Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25 (1997), 862–866.
103. [103] Kaposi-Novak, P., Lee, J.S., Gomez-Quiroz, L., Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116 (2006), 1582–1595.
104. [104] A. Santoro, L. Rimassa, Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J.L., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14 (2013), 55–63.
105. [105] Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (2002), 442–454.
106. [106] Dituri, F., Mazzocca, A., Peidro, F.J., Papappicco, P., Fabregat, I., De Santis, F., et al. Differential Inhibition of the TGF-beta Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-beta Receptor Type II. PLoS One, 8, 2013, e67109.
107. [107] Fransvea, E., Mazzocca, A., Santamato, A., Azzariti, A., Antonaci, S., Giannelli, G., Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol 68 (2011), 79–86.
108. [108] Dituri, F., Serio, G., Filannino, D., Mascolo, A., Sacco, R., Villa, E., et al. Circulating TGF-beta1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. Cancer Lett 353 (2014), 264–271.
109. [109] S.P. Chen, B.X. Liu, J. Xu, Pei, X.F., Liao, Y.J., Yuan, F., et al. MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets. BMC Cancer, 15, 2015, 706.
110. [110] Fan, L.C., Shiau, C.W., Tai, W.T., Hung, M.H., Chu, P.Y., Hsieh, F.S., et al. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene 34 (2015), 5252–5263.
111. [111] Nath, A., Li, I., Roberts, L.R., Chan, C., Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep, 5, 2015, 14752.
112. [112] Z.C. Wang, Q. Gao, J.Y. Shi, W.J. Guo, Yang, L.X., Liu, X.Y., et al. Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition. Hepatology 62 (2015), 1201–1214.
113. [113] Xiao, S., Chang, R.M., Yang, M.Y., Lei, X., Liu, X., Gao, W.B., et al. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology 63 (2016), 1256–1271.
114. [114] Zhao, H., Lv, F., Liang, G., Huang, X., Wu, G., Zhang, W., et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3beta/beta- catenin signaling cascade via FGFR4 activation. Oncotarget 7 (2016), 13575–13586.
115. [115] Y. Zhu, Y. Cheng, Guo, Y., Chen, J., Chen, F., Luo, R., et al. Protein kinase D2 contributes to TNF-alpha-induced epithelial mesenchymal transition and invasion via the PI3K/GSK-3beta/beta-catenin pathway in hepatocellular carcinoma. Oncotarget 7 (2016), 5327–5341.